Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 2
1987 1
1988 2
1991 2
1992 3
1993 1
1994 3
1995 2
1996 4
1997 2
1998 9
1999 5
2000 2
2001 6
2002 5
2003 9
2004 7
2005 18
2006 22
2007 23
2008 21
2009 34
2010 36
2011 42
2012 61
2013 73
2014 49
2015 69
2016 83
2017 123
2018 119
2019 122
2020 136
2021 147
2022 197
2023 186
2024 266
2025 241

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,916 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Oh DY, et al. Among authors: he ar. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398 Clinical Trial.
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M; CheckMate 9DW investigators. Yau T, et al. Among authors: he a. Lancet. 2025 May 24;405(10492):1851-1864. doi: 10.1016/S0140-6736(25)00403-9. Epub 2025 May 8. Lancet. 2025. PMID: 40349714 Free article. Clinical Trial.
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG. Zhao WH, et al. Among authors: he al. J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6. J Hematol Oncol. 2018. PMID: 30572922 Free PMC article. Clinical Trial.
CoBATCH for High-Throughput Single-Cell Epigenomic Profiling.
Wang Q, Xiong H, Ai S, Yu X, Liu Y, Zhang J, He A. Wang Q, et al. Among authors: he a. Mol Cell. 2019 Oct 3;76(1):206-216.e7. doi: 10.1016/j.molcel.2019.07.015. Epub 2019 Aug 27. Mol Cell. 2019. PMID: 31471188 Free article.
N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.
Wang S, Gao S, Zeng Y, Zhu L, Mo Y, Wong CC, Bao Y, Su P, Zhai J, Wang L, Soares F, Xu X, Chen H, Hezaveh K, Ci X, He A, McGaha T, O'Brien C, Rottapel R, Kang W, Wu J, Zheng G, Cai Z, Yu J, He HH. Wang S, et al. Among authors: he a. Gastroenterology. 2022 Apr;162(4):1183-1196. doi: 10.1053/j.gastro.2021.12.269. Epub 2021 Dec 28. Gastroenterology. 2022. PMID: 34968454 Free article.
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, Heitzeneder S, Tousley A, Lattin J, Xu P, Huang J, Nasholm N, He A, Kuo TC, Sangalang ERB, Pons J, Barkal A, Brewer RE, Marjon KD, Vilches-Moure JG, Marshall PL, Fernandes R, Monje M, Cochran JR, Sorensen PH, Daldrup-Link HE, Weissman IL, Sage J, Majeti R, Bertozzi CR, Weiss WA, Mackall CL, Majzner RG. Theruvath J, et al. Among authors: he a. Nat Med. 2022 Feb;28(2):333-344. doi: 10.1038/s41591-021-01625-x. Epub 2022 Jan 13. Nat Med. 2022. PMID: 35027753 Free PMC article.
1,916 results